Render Target: STATIC
Render Timestamp: 2024-11-21T13:22:04.979Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-30 01:59:39.707
Product last modified at: 2024-10-03T14:15:14.514Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

ANGPTL3 (F8N1Q) Rabbit mAb #26533

Filter:
  • WB

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 30-38, 55-65
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Simple Western™ 1:10 - 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    ANGPTL3 (FN1Q) Rabbit mAb recognizes endogenous levels of total ANGPTL3 protein. This antibody recognizes both the full-length protein (UniProt #Q9Y5C1) and the cleaved C-terminal fibrinogen-like domain (ANGPTL3-FLD).

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human ANGPTL3 protein.

    Background

    Angiopoietin-like 3 (ANGPTL3) is a secreted protein primarily expressed in liver and a regulator of fatty acid homeostasis (1). The angiopoietin-like family contains a signal peptide, an N-terminal coiled-coil domain (CCD), a linker peptide, and a C-terminal fibrinogen-like domain (FLD). Cleavage of the CCD and FLD occurs within the linker peptide, and is required for the activity of both domains (2). ANGPTL3-CCD, in concert with ANGPTL4/ANGPTL8, increases circulating triglyceride levels by inhibiting lipoprotein lipase, a hydrolase of LDL cholesterol (2,3). ANGPTL3-CCD also directly inhibits endothelial lipase, the enzyme responsible for HDL cholesterol hydrolysis (8,9). Thus, ANGPTL3-deficient mice have low levels of plasma HDL cholesterol, a risk factor for atherosclerosis (8,9). Unlike traditional angiopoietins, ANGPTL3-FLD does not bind the Tie2 receptor (4). ANGPTL3-FLD has been demonstrated to stimulate angiogenesis in endothelial cells via binding to integrin αVβ3, and to facilitate lipolysis in adipocytes via stimulation of the PDGFRβ-BRAF-ERK pathway (4,5). ANGPTL3 is currently a therapeutic target in patients with high-LDL dyslipidaemia, and can be inhibited with the use of monoclonal antibodies or antisense nucleotides (6,7).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.